INmune Bio Files For Common Stock Offering Of $65M Shares Of Common Stock

Up to $65,000,000 of Shares of Common Stock

 

INMUNE BIO INC.

We have entered into a sales agreement with A.G.P./Alliance Global Partners ("A.G.P." or "the Sales Agent"), dated December 19, 2025 (the "Sales Agreement"), relating to the sale of shares of our common stock, $0.001 par value per share (the "common stock"), offered by this prospectus supplement and the accompanying base prospectus. As described below, we are offering under this prospectus supplement and the accompanying base prospectus up to $65 million of shares of our common stock through the Sales Agent.

Our common stock is listed on the Nasdaq Capital Market ("Nasdaq" or the "Nasdaq Capital Market") under the symbol "INMB." On December 18, 2025, the last reported sale price of our common stock on Nasdaq was $1.82 per share.

Sales of our common stock, if any, under this prospectus supplement may be made in sales deemed to be an "at the market offering" as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended (the "Securities Act"). A.G.P. is not required to sell any specific number or dollar amount of our common stock, but will act as a Sales Agent using commercially reasonable efforts consistent with its normal trading and sales practices, on mutually agreed terms between A.G.P. and us. The shares of our common stock to which this prospectus supplement relates will be sold through A.G.P. on any given day. There is no arrangement for funds to be received in any escrow, trust or similar arrangement.

  

The compensation to A.G.P. for sales of shares of our common stock sold pursuant to the Sales Agreement will be equal to 3.0% of the gross proceeds from each such sale. In connection with the sale of shares of common stock on our behalf, A.G.P. will be deemed to be an "underwriter" within the meaning of the Securities Act, and the compensation of A.G.P. will be deemed to be underwriting commissions or discounts. We have also agreed to provide indemnification and contribution to A.G.P. with respect to certain liabilities, including liabilities under the Securities Act.